{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination induces type I interferon signaling and is associated with expanded antigen presentation on MHC-I.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        },
        {
          "quote": "| Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |",
          "line_ref": "L29"
        },
        {
          "quote": "A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.",
          "line_ref": "L44"
        }
      ],
      "caveat": "The report summarizes mechanistic steps, but notes that some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
    },
    {
      "claim_id": "C02",
      "claim": "The combined intervention improves tumor control in mice and aligns with better outcomes in a retrospective human cohort stratified by SARS-CoV-2 mRNA vaccination status.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        },
        {
          "quote": "| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |",
          "line_ref": "L30"
        },
        {
          "quote": "- Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.",
          "line_ref": "L15"
        }
      ],
      "caveat": "The human analysis is retrospective and non-randomized; residual confounding is likely, so alignment with better outcomes does not establish causality."
    },
    {
      "claim_id": "C03",
      "claim": "The reported sensitization effect is conditional on the mRNA-triggered type I interferon pathway, based on particle controls and IFNAR1 blockade results.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Lipid particle controls lacking mRNA did not reproduce the sensitization effect.",
          "line_ref": "L38"
        },
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        }
      ],
      "caveat": "These perturbation controls are described in the report, but the overall findings are from preclinical systems and may not map one-to-one to all human tumors."
    },
    {
      "claim_id": "C04",
      "claim": "Prospective randomized studies are required before changing clinical protocols based on the reported tumor-sensitization effects.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "The human analysis is retrospective and non-randomized; residual confounding is likely.",
          "line_ref": "L49"
        },
        {
          "quote": "The study supports a biologically coherent hypothesis that intratumoral mRNA vaccination can prime tumors for stronger ICI responses, but prospective randomized studies are required before clinical protocol changes are justified.",
          "line_ref": "L55"
        }
      ],
      "caveat": "This is a cautious interpretive conclusion; it does not quantify how large a benefit would be expected in a future randomized trial."
    }
  ]
}
